{
  "docId": "019de070-182a-72ba-952e-2b048c610e12",
  "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 22,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/14",
  "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12",
  "deckJsonHref": "/decks/019de070-182a-72ba-952e-2b048c610e12.json",
  "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.36,
        "y": 0.238
      },
      "kind": "list",
      "text": "PEACE: A single, global pivotal trial designed with input from FDA and EMA: Primary endpoint: arginine reduction; secondary endpoints: clinical outcomes, safety and PK; 30 patients, randomized 2:1 (pegzilarginase:placebo); 24 weeks dosing period; Enrollment completion in 3Q2020; topline results in 1Q2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03687df5-9624-4fd0-a55e-48faf7495fe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.66,
        "y": 0.238
      },
      "kind": "list",
      "text": "Opportunity: Estimated >2,500 patients worldwide; >240 patients identified worldwide (>125 patients in U.S.); Worldwide commercial rights with ongoing ex-U.S. partnering discussions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84a3d831-2248-40a4-bd85-9cc2ee7f9935",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.238
      },
      "kind": "list",
      "text": "Phase 1/2 & OLE data demonstrates clinical impact: Sustained control of plasma arginine; 85% (11/13) of patients at the 56 week analysis were clinical responders; Well tolerated and the rates of treatment-related adverse events decreased over time",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f01c6200-b0d6-4682-bbbf-79c4f9eb0eb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Arginase 1 Deficiency Key Highlights and Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c5bf063-8ae7-49fd-b5d2-8dd341cb8741",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "da6f036f-5b24-4731-926a-17e53c7fe13a",
      "evidence": "list/bullet: PEACE: A single, global pivotal trial designed with input from FDA and EMA: Primary endpoint: arginine reduction; secondary endpoints: clinical outcomes, safety and PK; 30 patients, randomized 2:1 (pegzilarg",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}